Inoue S, Egawa M, Satoh S, Saito M, Suzuki H, Kumahara Y, Abe M, Kumagai A, Goto Y, Shizume K
Third Department of Internal Medicine, Yokohama City University, Japan.
Am J Clin Nutr. 1992 Jan;55(1 Suppl):199S-202S. doi: 10.1093/ajcn/55.1.199s.
The Japanese Mazindol study group investigated the action of an anorexiant, mazindol, and found that it reduced food intake by directly suppressing neurons in the lateral hypothalamus, inhibited gastric acid secretion, increased motor activity, decreased glucose absorption, and inhibited insulin secretion. It thus appears that the main effect of mazindol is to decrease food intake through suppressing feeding centers in the hypothalamus. A multicenter open study of mazindol in Japan revealed that loss of body weight and relative body weight in 14 wk were 4.6 kg and 9.2%, respectively, with suppression of appetite in the majority of obese patients. A multicenter double-blind study demonstrated that mazindol was superior to the placebo in the treatment of simple obesity. We also suggest that mazindol is effective in the maintenance of reduced body weight after obesity therapy and in the treatment of obesity-related diseases such as diabetes, hypertension, or hyperlipidemia.
日本马吲哚研究小组研究了一种食欲抑制剂马吲哚的作用，发现它通过直接抑制下丘脑外侧的神经元来减少食物摄入量，抑制胃酸分泌，增加运动活性，减少葡萄糖吸收，并抑制胰岛素分泌。因此，马吲哚的主要作用似乎是通过抑制下丘脑的进食中枢来减少食物摄入量。在日本进行的一项关于马吲哚的多中心开放性研究显示，14周内体重减轻和相对体重下降分别为4.6千克和9.2%，大多数肥胖患者的食欲受到抑制。一项多中心双盲研究表明，在治疗单纯性肥胖方面，马吲哚优于安慰剂。我们还认为，马吲哚在肥胖治疗后维持减轻的体重以及治疗肥胖相关疾病如糖尿病、高血压或高脂血症方面是有效的。
